BeiGene Dirección

Dirección controles de criterios 2/4

El CEO de BeiGene es John Oyler , nombrado en Jan 2010, tiene una permanencia de 14.83 años. compensación anual total es CN¥134.33M, compuesta por 4.6% salario y 95.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 3.52% de las acciones de la empresa, por valor de HK$6.00B. La antigüedad media del equipo directivo y de la junta directiva es de 3.2 años y 4.3 años, respectivamente.

Información clave

John Oyler

Chief Executive Officer (CEO)

CN¥134.3m

Compensación total

Porcentaje del salario del CEO	4.6%
Permanencia del CEO	14.8yrs
Participación del CEO	3.5%
Permanencia media de la dirección	3.2yrs
Promedio de permanencia en la Junta Directiva	4.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de John Oyler en comparación con los beneficios de BeiGene?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-CN¥6b
Jun 30 2024	n/a	n/a	-CN¥4b
Mar 31 2024	n/a	n/a	-CN¥6b
Dec 31 2023	CN¥134m	CN¥6m	-CN¥6b
Sep 30 2023	n/a	n/a	-CN¥7b
Jun 30 2023	n/a	n/a	-CN¥13b
Mar 31 2023	n/a	n/a	-CN¥13b
Dec 31 2022	CN¥124m	CN¥6m	-CN¥14b
Sep 30 2022	n/a	n/a	-CN¥15b
Jun 30 2022	n/a	n/a	-CN¥14b
Mar 31 2022	n/a	n/a	-CN¥12b
Dec 31 2021	CN¥106m	CN¥5m	-CN¥9b
Sep 30 2021	n/a	n/a	-CN¥9b
Jun 30 2021	n/a	n/a	-CN¥9b
Mar 31 2021	n/a	n/a	-CN¥8b
Dec 31 2020	CN¥94m	CN¥5m	-CN¥11b
Sep 30 2020	n/a	n/a	-CN¥10b
Jun 30 2020	n/a	n/a	-CN¥10b
Mar 31 2020	n/a	n/a	-CN¥8b
Dec 31 2019	CN¥88m	CN¥5m	-CN¥7b
Sep 30 2019	n/a	n/a	-CN¥6b
Jun 30 2019	n/a	n/a	-CN¥5b
Mar 31 2019	n/a	n/a	-CN¥5b
Dec 31 2018	CN¥192m	CN¥4m	-CN¥5b
Sep 30 2018	n/a	n/a	-CN¥3b
Jun 30 2018	n/a	n/a	-CN¥2b
Mar 31 2018	n/a	n/a	-CN¥923m
Dec 31 2017	CN¥67m	CN¥3m	-CN¥606m

Compensación vs. Mercado: La compensación total de John($USD18.55M) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD905.89K).

Compensación vs. Ingresos: La compensación de John ha aumentado mientras la empresa no es rentable.

CEO

John Oyler (56 yo)

14.8yrs

Permanencia

CN¥134,331,046

Compensación

Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009....

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
John Oyler	Co-Founder	14.8yrs	CN¥134.33m	3.52% HK$ 6.0b
Xiaobin Wu	President & COO	6.5yrs	CN¥78.08m	0.056% HK$ 94.6m
Xiaodong Wang	Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder	14.8yrs	CN¥31.35m	0.83% HK$ 1.4b
Chan Lee	General Counsel & Senior VP	2.3yrs	CN¥28.74m	0.017% HK$ 29.3m
Wang Lai	Global Head of R&D	no data	CN¥51.93m	0.13% HK$ 220.0m
Aaron Rosenberg	CFO & Principal Financial Officer	less than a year	sin datos	sin datos
Titus Ball	VP & Chief Accounting Officer	less than a year	sin datos	0.0033% HK$ 5.7m
Liza Heapes	Head of Investor Relations	no data	sin datos	sin datos
Yang Ji	Chief Compliance Officer	1.1yrs	sin datos	sin datos
Yan Qi	Senior VP & Head of Public Affairs - Greater China	3.8yrs	sin datos	sin datos
Mark Lanasa	Senior VP & Chief Medical Officer for Solid Tumors	2.8yrs	sin datos	sin datos
Graham Hardiman	Global Head of Human Resources	3.7yrs	sin datos	sin datos

3.2yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 6160 se considera experimentado (3.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
John Oyler	Co-Founder	14.1yrs	CN¥134.33m	3.52% HK$ 6.0b
Xiaodong Wang	Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder	8.8yrs	CN¥31.35m	0.83% HK$ 1.4b
Steven Young	Acting Head of Medicinal Chemistry & Member of Scientific Advisory Board	3.6yrs	sin datos	sin datos
Michael Goller	Independent Non-Executive Director & Member of the Scientific Advisory Committee	9.6yrs	CN¥3.42m	0.0034% HK$ 5.8m
Corazon Sanders	Independent Non-Executive Director & Member of Scientific Advisory Committee	4.3yrs	CN¥3.56m	0.0022% HK$ 3.7m
Anthony Hooper	Independent Non-Executive Director	4.8yrs	CN¥3.64m	0.0027% HK$ 4.6m
Shalini Sharp	Director	less than a year	sin datos	sin datos
Alessandro Riva	Co-Chairman of Scientific Advisory Committee & Independent Non-Executive Director	2.8yrs	CN¥3.49m	0.0021% HK$ 3.6m
Olivier Brandicourt	Independent Non-Executive Director	less than a year	sin datos	0% HK$ 0
Ranjeev Krishana	Independent Lead Director	10.1yrs	CN¥3.46m	0.0034% HK$ 5.8m
Margaret Han Dugan	Member of Scientific Advisory Board & Independent Non-Executive Director	2.8yrs	CN¥3.62m	0.0021% HK$ 3.6m

4.3yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de 6160 se considera experimentada (4.3 años de antigüedad promedio).

BeiGene Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

BeiGene, Ltd. Announces Passing Away of Donald Glazer, A Board Member and the Chair of the Nominating and Corporate Governance Committee

BeiGene, Ltd. Appoints Shalini Sharp to Board of Directors and Member of the Audit Committee, Effective September 27, 2024

Beigene, Ltd. Appoints Aaron Rosenberg as the Principal Financial Officer, Effective from July 22, 2024

BeiGene, Ltd. Announces CFO Changes

BeiGene, Ltd., Annual General Meeting, Jun 05, 2024

Beigene, Ltd. Announces Board Changes

Recent updates

European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer

BeiGene, Ltd. Announces Passing Away of Donald Glazer, A Board Member and the Chair of the Nominating and Corporate Governance Committee

BeiGene, Ltd. to Report Q3, 2024 Results on Nov 13, 2024

BeiGene, Ltd. Appoints Shalini Sharp to Board of Directors and Member of the Audit Committee, Effective September 27, 2024

BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy

BeiGene, Ltd. to Report Q2, 2024 Results on Aug 07, 2024

Beigene, Ltd. Appoints Aaron Rosenberg as the Principal Financial Officer, Effective from July 22, 2024

BeiGene, Ltd. Announces CFO Changes

BeiGene, Ltd. to Report First Half, 2024 Results on Aug 30, 2024

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024

BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

BeiGene, Ltd., Annual General Meeting, Jun 05, 2024

BeiGene, Ltd. to Report Q1, 2024 Results on May 11, 2024

BeiGene, Ltd. Receives FDA Approval for TEVIMBRA for Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

BeiGene, Ltd. Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma

BeiGene, Ltd. to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024

BeiGene, Ltd. Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

BeiGene, Ltd. Announces Adults Living with Chronic Lymphocytic Leukemia in Ontario and Quebec Now Have Access, Through Public Reimbursement, to BRUKINSA® (Zanubrutinib)

Beigene, Ltd. Announces Board Changes

BeiGene, Ltd. Announces FDA Approves Label Update for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

BeiGene, Ltd. Receives European Commission Approval for BRUKINSA®? (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Beigene, Ltd. Receives Positive Recommendation from Nice in U.K. for Adult Patients with Chronic Lymphocytic Leukemia

BeiGene, Ltd. Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeli

BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

U.S. FDA Accepts Biologics License Application in First-Line Advanced ESCC

BeiGene, Ltd. Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA(R)

Beigene, Ltd. Announces Change of Chair of Audit Committee

Beigene Announces Positive CHMP Opinion for Tislelizumab as Treatment for Advanced or Metastatic ESCC

Beigene, Ltd. Announces FDA Acceptance of sNDA for Fifth Brukinsa(R) Indication

BeiGene, Ltd. to Report First Half, 2023 Results on Aug 30, 2023

BeiGene Highlights Significant Brukinsa® (Zanubrutinib) Data at 17th International Conference on Malignant Lymphoma

Pharmacyclics LLC Files Complaint Against Beigene, Ltd. and Beigene USA, Inc

BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress

BeiGene, Ltd. Announces Approval of BRUKINSA (Zanubrutinib) by Health Canada for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia

BeiGene, Ltd. Announces Presentations At the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio

Beigene, Ltd. Provides Update Regarding Recent Business Developments

BeiGene Announces BRUKINSA Approved in the U.S. for Chronic Lymphocytic Leukemia

Brukinsa (Zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma in Great Britain by MHRA

BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List

BeiGene, Ltd. Announces Center for Drug Evaluation of the China National Medical Products Administration Accepts Supplemental Biologics License Application

BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab

Beigene, Ltd.'S Brukinsa Demonstrated Superior Progression-Free Survival over Imbruvica (Ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker At ASH

Beigene to Present Final Pfs Results from Alpine Trial Demonstrating Superior Pfs for Brukinsa® Versus Imbruvica® in Late-Breaking Oral Session At Ash 2022

Beigene, Ltd. Announces Change of Co-Chair of Scientific Advisory Committee

BeiGene Receives European Commission Approval for Brukinsa® (Zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (Cll)

Beigene, Ltd. Announces Brazil Approvals for Brukinsa® as A Treatment for Rare Blood Cancers

Abbisko Therapeutics Co., Ltd. Completes First Patient Enrollment in Phase II Clinical Trial for Investigational Pan-FGFR Inhibitor ABSK091 in Combination with Anti-PD-1 Antibody Tislelizumab Developed by BeiGene, Ltd. in Urothelial Carcinoma

BeiGene Receives European Commission Approval for BRUKINSA(R) (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma

BeiGene, Ltd. Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL

Beigene Announces Positive Topline Results from Final Progression-Free Survival Analysis of Brukinsa® (Zanubrutinib) Compared to Imbruvica® (Ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (Cll) Trial

NICE Recommends Beigene’s BRUKINSA® (Zanubrutinib) for Patients with Waldenström’s Macroglobulinemia Who Have Had At Least One Treatment

Beigene, Ltd. Announces Appointment of Member of Compensation Committee

BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer

BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China

BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer

Beigene Provides Regulatory Update on the U.S. Biologics License Application (Bla) for Pd 1 Inhibitor Tislelizumab in 2L Escc

BeiGene, Ltd. Appoints Chan Lee as General Counsel, July 18 2022

Leap Therapeutics and BeiGene, Ltd. Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer

BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Beigene, Ltd. Announces Executive Changes

Beigene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab

Ministry of Health in Kuwait Approves Beigene, Ltd.'s BRUKINSA™ (Zanubrutinib) in 50 Markets

BeiGene, Ltd. Announces NMPA Grants its Anti-PD-1 Antibody Tislelizumab Approval for First-Line Treatment of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer and Conditional Approval for Treatment of Patients with Hepatocellular Carcinoma

Beigene Announces the Approval in China of BLINCYTO® for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

BeiGene, Ltd., Annual General Meeting, Jun 22, 2022